What is claimed is:

1. Use of an interleukin-4 receptor (IL-4R) antagonist for the manufacture of a medicament for enhancing the efficacy, safety, and/or tolerability of a peanut allergen immunotherapy regimen in a subject having a peanut allergy, wherein one or more doses of the IL-4R antagonist is to be administered to the subject in combination with the immunotherapy regimen, wherein at least one dose of the IL-4R antagonist is to be administered prior to the start of the immunotherapy regimen, and wherein the IL-4R antagonist is an anti-IL-4R antibody, or an antigen-binding fragment thereof, that comprises the heavy chain complementarity determining regions (HCDRs) of a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:1 and the light chain complementarity determining regions (LCDRs) of a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO:2.

2. The use of claim 1, wherein the immunotherapy regimen is an oral immunotherapy (OIT) regimen.

3. The use of claim 1 or 2, wherein the peanut allergen is a composition comprising peanut flour.

4. The use of any one of claims 1 to 3, wherein the immunotherapy regimen comprises an up-dosing phase followed by a maintenance phase, wherein the up-dosing phase comprises increasing doses of the peanut allergen to be administered over a period of at least 24 weeks and wherein the maintenance phase comprises one or more maintenance doses of the peanut allergen to be administered at the highest dose during the up-dosing phase.

5. The use of claim 4, wherein the up-dosing phase comprises an initial dose escalation day (IDED) regimen followed by increasing dose escalations every two weeks.

6 .The use of claim 4 or 5, wherein the up-dosing phase comprises up-dosing from an initial dose of 0.5 mg peanut protein to a dose of 300 mg peanut protein and wherein the maintenance phase comprises one or more maintenance doses of 300 mg peanut protein to be administered.

7. The use of any one of claims 1 to 6, wherein the subject is aged ≥ 6 years old to < 18 years old.

8. The use of any one of claims 1 to 7, wherein the subject has one or more of the following baseline characteristics:

(a) a clinical history of allergy to peanuts or peanut-containing foods;

(b) experiences dose-limiting symptoms at or before a challenge dose of 100 mg peanut protein, or at a cumulative dose of ≤144 mg of peanut protein, in a double-blind, placebo-controlled food challenge (DBPCFC);

(c) has a serum IgE to peanut of ≥10 kUA/L; or

(d) has a skin prick test (SPT) to peanut ≥8 mm.

9. The use of any one of claims 1 to 8, wherein the subject has concomitant atopic dermatitis, asthma, eosinophilic esophagitis, and/or multiple food allergies.

10. The use of any one of claims 1 to 9, wherein the IL-4R antagonist is to be administered at a dose of about 50 mg to about 600 mg.

11. The use of any one of claims 1 to 10, wherein the IL-4R antagonist is to be administered as an initial dose followed by one or more secondary doses, wherein each secondary dose is to be administered 1 to 4 weeks after the immediately preceding dose.

12. The use of claim 11, wherein each secondary dose of the IL-4R antagonist is to be administered two weeks after the immediately preceding dose.

13. The use of any one of claims 1 to 12, wherein the IL-4R antagonist is to be administered subcutaneously or intravenously.

14. The use of any one of claims 1 to 11, wherein the IL-4R antagonist is to be subcutaneously administered at an initial dose followed by one or more secondary doses, wherein each secondary dose is to be administered 1 to 4 weeks after the immediately preceding dose, and wherein:

(i) for a subject weighing <30 kg, the initial dose of the IL-4R antagonist is 200 mg and each secondary dose is 100 mg; or

(ii) for a subject having a body weight of ≥30 kg to <60 kg, the initial dose of the IL-4R antagonist is 400 mg and each secondary dose is 200 mg; or

(iii) for a subject having a body weight of ≥60 kg, the initial dose of the IL-4R antagonist is 600 mg and each secondary dose is 300 mg.

15. The use of claim 14, wherein the subject has a body weight of <30 kg and the IL-4R antagonist is to be administered at an initial dose of 200 mg followed by one or more secondary doses of 100 mg every two weeks (Q2W).

16. The use of claim 14, wherein the subject has a body weight of ≥30 kg to <60 mg and the IL-4R antagonist is to be administered at an initial dose of 400 mg followed by one or more secondary doses of 200 mg every two weeks (Q2W).

17. The use of claim 14, wherein the subject has a body weight of ≥60 mg and the IL-4R antagonist is to be administered at an initial dose of 600 mg followed by one or more secondary doses of 300 mg every two weeks (Q2W).

18. The use of any one of claims 11 to 17, wherein the initial dose of the IL-4R antagonist is to be administered at least two weeks before the start of the immunotherapy regimen.

19. The use of claim 18, wherein the IL-4R antagonist is to be administered for at least four weeks before the start of the immunotherapy regimen.

20. The use of any one of claims 1 to 19, wherein the IL-4R antagonist to be administered:

(i) increases the cumulative tolerated dose of peanut protein as measured by a DBPCFC; and/or

(ii) decreases the frequency and/or severity of peanut allergic symptoms, gastrointestinal symptoms, and/or itching symptoms.

21. The use of any one of claims 1 to 20, wherein the anti-IL-4R antibody or antigen-binding fragment thereof comprises three HCDRs (HCDR1, HCDR2 and HCDR3) and three LCDRs (LCDR1, LCDR2 and LCDR3), wherein the HCDR1 comprises the amino acid sequence of SEQ ID NO:3; the HCDR2 comprises the amino acid sequence of SEQ ID NO:4; the HCDR3 comprises the amino acid sequence of SEQ ID NO:5; the LCDR1 comprises the amino acid sequence of SEQ ID NO:6; the LCDR2 comprises the amino acid sequence of SEQ ID NO:7; and the LCDR3 comprises the amino acid sequence of SEQ ID NO:8.

22. The use of any one of claims 1 to 21, wherein the anti-IL-4R antibody or antigen-binding fragment thereof comprises a HCVR comprising the amino acid sequence of SEQ ID NO:1 and comprises a LCVR comprising the amino acid sequence of SEQ ID NO:2.

23. The use of any one of claims 1 to 22, wherein the anti-IL-4R antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:9 and a light chain comprising the amino acid sequence of SEQ ID NO:10.

24. The use of any one of claims 1 to 23, wherein the IL-4R antagonist is dupilumab.

25. The use of any one of claims 1 to 24, wherein the IL-4R antagonist is contained in a container selected from the group consisting of a glass vial, a syringe, a pre-filled syringe, a pen delivery device, and an autoinjector.

26. The use of claim 25, wherein the IL-4R antagonist is contained in a pre-filled syringe.

27. The use of claim 26, wherein the pre-filled syringe is a single-dose pre-filled syringe.

28. The use of claim 25, wherein the IL-4R antagonist is contained in an autoinjector.

29. The use of claim 25, wherein the IL-4R antagonist is contained in a pen delivery device.